Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience

Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., ...More

FUTURE ONCOLOGY, vol.18, pp.323-331, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 18
  • Publication Date: 2022
  • Doi Number: 10.2217/fon-2021-0303
  • Journal Name: FUTURE ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.323-331
  • Keywords: adjuvant paclitaxel plus trastuzumab, APT trial, HER2-overexpressing breast cancer, node negative, real-life experience, PRIMARY THERAPY, JOINT ANALYSIS, FOLLOW-UP, CHEMOTHERAPY, WOMEN, SURVIVAL, OUTCOMES, TRIAL
  • Hacettepe University Affiliated: Yes


Lay abstract In oncology practice, there have been some efforts to avoid the toxicity of combination chemotherapies and reduce the amount of treatment given in recent decades. These strategies have been studied especially for patients with a specific subtype of early-stage breast cancer. We present the results from patients treated in our centers and discuss them in relation to the literature.